Thelansis’s “Chronic Neutropenia (CN) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Chronic neutropenia encompasses a heterogeneous group of disorders characterized by persistently reduced circulating neutrophils, with infection risk varying substantially according to severity and underlying cause. Severe congenital and cyclic neutropenia can lead to recurrent infections and are effectively managed with granulocyte colony-stimulating factor (G-CSF), which has substantially improved survival and reduced infection-related morbidity. In autoimmune and chronic idiopathic neutropenia, however, continuous G-CSF is generally reserved for patients with recurrent or severe infections rather than used solely according to neutrophil counts. Although G-CSF is generally well tolerated, regular subcutaneous administration and adverse effects such as bone pain can create a meaningful treatment burden. This has driven interest in alternative mechanisms and oral therapies. Mavorixafor, a CXCR4 antagonist that mobilizes neutrophils into the circulation, is being evaluated in a Phase 3 study involving congenital, autoimmune, and idiopathic chronic neutropenic disorders with recurrent or serious infections and received FDA orphan-drug designation for congenital neutropenia in 2026. For stakeholders, chronic neutropenia represents a differentiated hematology opportunity where the next advances are likely to focus on reducing injection burden, improving infection protection, and tailoring treatment to the underlying biological mechanism.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Chronic Neutropenia (CN) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Chronic Neutropenia (CN) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.